These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16093841)

  • 1. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis.
    Adams A; Lehman TJ
    Curr Opin Rheumatol; 2005 Sep; 17(5):612-6. PubMed ID: 16093841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis).
    Agle LM; Rosenkranz M; Lehman TJ
    Expert Opin Investig Drugs; 2003 Jan; 12(1):19-28. PubMed ID: 12517251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 in juvenile idiopathic arthritis.
    Akioka S
    Mod Rheumatol; 2019 Mar; 29(2):275-286. PubMed ID: 30686091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis.
    Yokota S
    Curr Opin Rheumatol; 2003 Sep; 15(5):581-6. PubMed ID: 12960484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the medical treatment of juvenile rheumatoid arthritis.
    Onel KB
    Curr Opin Pediatr; 2000 Feb; 12(1):72-5. PubMed ID: 10676778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies.
    Pardeo M; Bracaglia C; De Benedetti F
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):505-516. PubMed ID: 29773270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
    Kalliolias GD; Liossis SN
    Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile idiopathic arthritis: therapies in the 21st century.
    Haines KA
    Bull NYU Hosp Jt Dis; 2007; 65(3):205-11. PubMed ID: 17922671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
    Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
    Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.
    Kumar S
    Indian J Pediatr; 2016 Apr; 83(4):322-7. PubMed ID: 26916892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the pathogenesis and treatment of systemic idiopathic arthritis.
    Sikora KA; Grom AA
    Curr Opin Pediatr; 2011 Dec; 23(6):640-6. PubMed ID: 22045308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome".
    Yokota S; Kikuchi M; Nozawa T; Kanetaka T; Sato T; Yamazaki K; Sakurai N; Hara R; Mori M
    Mod Rheumatol; 2015 Jan; 25(1):1-10. PubMed ID: 24842480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis].
    Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Apr; 31(2):99-103. PubMed ID: 18446012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.
    Ter Haar NM; Tak T; Mokry M; Scholman RC; Meerding JM; de Jager W; Verwoerd A; Foell D; Vogl T; Roth J; Leliefeld PHC; van Loosdregt J; Koenderman L; Vastert SJ; de Roock S
    Arthritis Rheumatol; 2018 Jun; 70(6):943-956. PubMed ID: 29426067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of methotrexate on the temporomandibular joint and facial morphology in juvenile rheumatoid arthritis patients.
    Ince DO; Ince A; Moore TL
    Am J Orthod Dentofacial Orthop; 2000 Jul; 118(1):75-83. PubMed ID: 10893476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide for systemic onset juvenile idiopathic arthritis.
    Sathe K; Khubchandani RP
    Indian Pediatr; 2013 Feb; 50(2):237-9. PubMed ID: 23474929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
    Pagnini I; Bertini F; Cimaz R
    Paediatr Drugs; 2016 Apr; 18(2):101-8. PubMed ID: 26939782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
    Verbsky JW; White AJ
    J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.